Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer

Cancer Science

Volumn 99, Issue 12, 2008, Pages 2349-2355

  Mano, Hiroyuki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE; HYBRID PROTEIN; ISOPROTEIN; MESSENGER RNA; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ASIAN; CARCINOGENICITY; CHROMOSOME 2; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME REPRESSION; ETHNIC GROUP; FUSION GENE; GENE IDENTIFICATION; GENE LOCUS; GENETIC SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; OLIGOMERIZATION; ONCOGENE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SOLID TUMOR;

CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 2; EXONS; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, GENETIC; NEOPLASMS; ONCOGENE PROTEINS, FUSION; TRANSLOCATION, GENETIC;

EID: 57349100409     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00972.x     Document Type: Review

References (71)

1. Futreal PA, Coin L, Marshall M et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-83.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-83.
3. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-412.
4. Pear WS, Miller JP, Xu L et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-92.
5. Oehler VG, Radich JP. Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. Curr Oncol Rep 2003; 5: 426-35.
6. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344: 1031-7.
7. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
8. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res 2000; 462: 247-53.
9. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
10. Mitelman F, Mertens F, Johansson B. Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. Genes Chromosomes Cancer 2005; 43: 350-66.
11. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 2004; 36: 331-4.
12. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7: 233-45.
13. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
14. Choi YL, Takeuchi K, Soda M et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008; 68: 4971-6.
15. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3: 13-17.
16. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
17. Tomlins SA, Laxman B, Dhanasekaran SM et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-9.
18. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
19. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
20. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-8.
21. Sharma SV, Settleman J. Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-31.
22. Goldfarb M, Shimizu K, Perucho M, Wigler M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 1982; 296: 404-9.
23. Aaronson SA. Growth factors and cancer. Science 1991; 254: 1146-53.
24. Choi YL, Moriuchi R, Osawa M et al. Retroviral expression screening of oncogenes in natural killer cell leukemia. Leuk Res 2005; 29: 943-9.
25. Fujiwara S, Yamashita Y, Choi YL et al. Transforming activity of the lymphotoxin-β receptor revealed by expression screening. Biochem Biophys Res Commun 2005; 338: 1256-62.
26. Kisanuki H, Choi YL, Wada T et al. Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. Eur J Cancer 2005; 41: 2170-5.
27. Choi YL, Kaneda R, Wada T et al. Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk Res 2007; 31: 203-9.
28. Fujiwara S, Yamashita Y, Choi YL et al. Transforming activity of purinergic receptor P2Y, G protein coupled, 8 revealed by retroviral expression screening. Leuk Lymphoma 2007; 48: 978-86.
29. Hatanaka H, Takada S, Choi YL et al. Transforming activity of purinergic receptor P2Y, G-protein coupled, 2 revealed by retroviral expression screening. Biochem Biophys Res Commun 2007; 356: 723-6.
30. Kitamura T, Onishi M, Kinoshita S, Shibuya A, Miyajima A, Nolan GP. Efficient screening of retroviral cDNA expression libraries. Proc Natl Acad Sci USA 1995; 92: 9146-50.
31. Yoshizuka N, Moriuchi R, Mori T et al. An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. J Biol Chem 2004; 279: 43 998-4004.
32. American Cancer Society. Global Cancer Facts and Figures 2007. [Cited 18 October, 2008.]Available from URL: http://www.cancer.org/downloads/STT/ Global_Facts_and_Figures_2007_rev2.pdf.
33. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
34. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
35. Pollmann M, Parwaresch R, Adam-Klages S, Kruse ML, Buck F, Heidebrecht HJ. Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp Cell Res 2006; 312: 3241-51.
36. Morris SW, Naeve C, Mathew P et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175-88.
37. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-4.
38. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80.kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994; 9: 1567-74.
39. Wan W, Albom MS, Lu L et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006; 107: 1617-23.
40. Galkin AV, Melnick JS, Kim S et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007; 104: 270-5.
41. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004; 199: 330-58.
42. Lacronique V, Boureux A, Valle VD et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309-12.
43. Shinmura K, Kageyama S, Tao H et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008; 61: 163-9.
44. Wong DD-S, So KK-T, Leung EL-H et al. EML4-ALK is a new oncogene in non-small cell lung carcinoma showing wild-type EGFR and K-RAS from non-smokers. American Association of Cancer Research Annual Meeting 12-16 April, 2008, San Diego, AACR (Philadelphia): (poster #LB-62).
45. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-83.
46. Takeuchi K, Choi YL, Soda M et al. Multiplex RT-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14: 6618-24.
47. Perner S, Wagner PL, Demichelis F et al. EML4-ALK fusion lung cancer: A rare acquired event. Neoplasia 2008; 10: 298-302.
48. Cataldo KA, Jalal SM, Law ME et al. Detection of t(2;5) in anaplastic large cell lymphoma: Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol 1999; 23: 1386-92.
49. Turner SD, Alexander DR. Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells. Leukemia 2006; 20: 572-82.
50. Matsumura I, Mizuki M, Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci 2008; 99: 479-85.
51. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997; 17: 2312-25.
52. Lee HH, Norris A, Weiss JB, Frasch M. Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 2003; 425: 507-12.
53. Stoica GE, Kuo A, Aigner A et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001; 276: 16 772-9.
54. Stoica GE, Kuo A, Powers C et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002; 277: 35 990-8.
55. Pulford K, Lamant L, Morris SW et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394-404.
56. Iwahara T, Fujimoto J, Wen D et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439-49.
57. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/ phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM). J Biol Chem 1996; 271: 21 446-52.
58. Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H. Isolation of a neuronal cell surface receptor of heparin binding growth-associated molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J Biol Chem 1994; 269: 12 999-3004.
59. Kuefer MU, Look AT, Pulford K et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90: 2901-10.
60. Miething C, Grundler R, Fend F et al. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. Oncogene 2003; 22: 4642-7.
61. Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003; 22: 7750-61.
62. McDermott U, Iafrate AJ, Gray NS et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-95.
63. Zhao B, Magdaleno S, Chua S et al. Transgenic mouse models for lung cancer. Exp Lung Res 2000; 26: 567-79.
64. McDermott U, Sharma SV, Dowell L et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007; 104: 19 936-41.
65. + anaplastic large cell lymphoma ('ALKoma'): The first case with a combination of 'not common'variants. Ann Oncol 2002; 13: 1827-32.
66. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
67. Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol 1995; 32: 545-61.
68. Furitsu T, Tsujimura T, Tono T et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-44.
69. Siehl J, Thiel E. C-kit, GIST, and imatinib. Recent Results Cancer Res 2007; 176: 145-51.
70. Armstrong F, Duplantier MM, Trempat P et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004; 23: 6071-82.
71. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-203.